Analysts predict that Rockwell Medical Inc (NASDAQ:RMTI) will report earnings per share (EPS) of ($0.14) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Rockwell Medical’s earnings, with estimates ranging from ($0.17) to ($0.11). Rockwell Medical posted earnings of ($0.10) per share in the same quarter last year, which suggests a negative year over year growth rate of 40%. The business is expected to announce its next quarterly earnings results on Friday, November 8th.
On average, analysts expect that Rockwell Medical will report full year earnings of ($0.64) per share for the current financial year, with EPS estimates ranging from ($0.72) to ($0.52). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.35) per share, with EPS estimates ranging from ($0.60) to ($0.01). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Rockwell Medical.
Rockwell Medical (NASDAQ:RMTI) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). Rockwell Medical had a negative return on equity of 143.68% and a negative net margin of 52.11%. The business had revenue of $14.85 million for the quarter, compared to analysts’ expectations of $16.42 million.
A number of equities analysts have issued reports on the stock. Piper Jaffray Companies assumed coverage on shares of Rockwell Medical in a research report on Monday, June 24th. They set an “overweight” rating and a $10.00 price target for the company. ValuEngine raised shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research lowered shares of Rockwell Medical from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. Ifs Securities lowered shares of Rockwell Medical from a “strong-buy” rating to an “outperform” rating in a research report on Wednesday, June 19th. Finally, Cantor Fitzgerald assumed coverage on shares of Rockwell Medical in a research report on Monday, June 24th. They set an “overweight” rating and a $11.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $9.65.
RMTI traded up $0.06 during trading on Friday, reaching $2.51. 157,920 shares of the company’s stock were exchanged, compared to its average volume of 274,852. Rockwell Medical has a 1 year low of $2.19 and a 1 year high of $6.88. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.25 and a quick ratio of 2.99. The stock has a market capitalization of $156.37 million, a P/E ratio of -5.34 and a beta of 1.47. The company’s fifty day simple moving average is $2.75 and its 200-day simple moving average is $3.70.
In other news, major shareholder David S. Richmond bought 68,750 shares of the business’s stock in a transaction dated Friday, July 19th. The stock was purchased at an average cost of $2.89 per share, with a total value of $198,687.50. Following the acquisition, the insider now directly owns 179,039 shares in the company, valued at $517,422.71. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider David S. Richmond bought 161,457 shares of the business’s stock in a transaction dated Monday, July 22nd. The shares were purchased at an average cost of $2.95 per share, with a total value of $476,298.15. Following the completion of the acquisition, the insider now owns 179,039 shares in the company, valued at $528,165.05. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 235,009 shares of company stock valued at $689,069. Insiders own 3.90% of the company’s stock.
Several large investors have recently bought and sold shares of the company. Royal Bank of Canada increased its holdings in shares of Rockwell Medical by 61.7% during the 2nd quarter. Royal Bank of Canada now owns 12,125 shares of the company’s stock valued at $37,000 after purchasing an additional 4,625 shares in the last quarter. Provident Investment Management Inc. increased its holdings in shares of Rockwell Medical by 14.3% during the 2nd quarter. Provident Investment Management Inc. now owns 40,000 shares of the company’s stock valued at $120,000 after purchasing an additional 5,000 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Rockwell Medical during the 1st quarter valued at approximately $57,000. Greenleaf Trust purchased a new position in shares of Rockwell Medical during the 2nd quarter valued at approximately $36,000. Finally, Morgan Stanley increased its holdings in shares of Rockwell Medical by 9.0% during the 2nd quarter. Morgan Stanley now owns 177,019 shares of the company’s stock valued at $534,000 after purchasing an additional 14,627 shares in the last quarter. 24.96% of the stock is owned by hedge funds and other institutional investors.
Rockwell Medical Company Profile
Rockwell Medical, Inc operates as a specialty pharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis. The company offers Triferic, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores; and Calcitriol, an active vitamin D injection for the management of hypocalcemia in patients undergoing chronic hemodialysis.
Featured Story: Penny Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.